Overview

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, phase I study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of SIM0237 in participants with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Collaborator:

Shanghai Xianxiang Medical Technology Co., Ltd.